DDrare: Database of Drug Development for Rare Diseases

Searched query = "Lipodystrophy", "Berardinelli-Seip syndrome", "Lawrence syndrome", "Barraquer-Simons syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 13 valent conjugated pneumococcal vaccine; 150 mg GSK1265744B; 300mg Gemcabene; 3TC; 600mg Gemcabene; ABC; ACETYL- L- CARNITINE; AKCEA-ANGPTL3-LRX; ATV; AZT; AZT/3TC; Abacavir; Abacavir 300mg twice daily; Abacavir sulfate; Abacavir sulfate, Lamivudine and Zidovudine; Acetate; Acetylcarnitine; Acipimox; Amprenavir; Antiretroviral/Anti HIV; Aramchol; Atazanavir; Atazanavir (ATV) + ritonavir (RTV), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (NRTIs); Atazanavir (Reyataz); Atazanavir/Ritonavir; Atorvastatin; Atorvastatin calcium; Avandia administration for 6-12 weeks; BMS-232632; Baricitinib; Behavioral: 60-minutes of steady state exercise; Behavioral: Diet; Behavioral: Exercise; Behavioral: Exercise Training; Behavioral: Exercise training; CD; CD-4 guided therapy interruption; COMBIVIR; Caffeine; Calcium; Carnitine; Cholic Acid; CoFactor; Cofactor supplementation (thiamine, riboflavin, L-carnitine); Combivir (zidovudine [AZT] / lamivudine [3TC]); Continuation of current HAART (boosted protease inhibitor [PI] combination + 2 NRTIs); Cyclophosphamide; DIOSMIN; Device: Venus Versa; Device: poly-L-lactic acid; Didanosine; Different HAART regimens; Diosmin; Diosminex, 500 mg, tabletki powlekane; Dolutegravir; Dolutegravir 50 MG; Efavirenz; Efavirenz (EFV); Emtricitabine; Emtricitabine/tenofovir; Enfuvirtide; Enfuvirtide (T20); Fenofibrate; GSK1265744B (sodium salt) containing 14C-GSK1265744B; Gemcabene; Genetic: Amplification by PCR and direct sequencing on the entire coding sequence and intron-exons boundaries of the candidate gene; Genotropin (human recombinant Growth hormone); Glycerine; Growth Hormone Releasing Hormone; Growth hormone; High-carbohdyrate breakfast; High-dose REGN4461; Hu Leptin (A-100); Human growth hormone; Human recombinant leptin (metreleptin); ISIS 304801; Indinavir; Kaletra (lopinavir [LPVr]); L-Carnitine; L-Lactic acid; Lactic acid; Lamivudine; Lamivudine/Zidovudine; Leptin; Lopinavir; Lopinavir/Ritonavir; Lopinavir/ritonavir + nevirapine; Lopinavir/ritonavir + zidovudine + lamivudine; Low-Dose REGN4461; METRELEPTIN; Mecasermin; Metformin; Metformin hydrochloride; Metreleptin; Metrelpetin; Monotherapy (Lopinavir/ritonavir); Monotherapy (Lopinavir/ritonavir) + ABC/3TC; Myalept; Nelfinavir; Nelfinavir mesylate; Nevirapine; Niacin; Non-nucleoside reverse transcriptase inhibitors; Norvir; NucleomaxX; Nucleoside analogue sparing HAART regimen; Nucleoside reverse transcriptase inhibitors; Obeticholic Acid; Obeticholic acid; Other: Glycerine gel; Other: Observation; POLY-L-LACTIC ACID; Perform blood cells and fibroblasts biochemical and immuno-labeled investigations; Pioglitazone; Pioglitazone or metformin; Pneumococcal polysaccharide vaccine 23 valent; Pravastatin; Pravastatin sodium; Prevenar13; Procedure: testosterone injection; Protease inhibitor; Protease inhibitors; R-metHuLeptin; REYATAZ 150MG 60 CPS BL; RTV; Raltegravir; Recombinant human growth hormone; Recombinant human growth hormone + rosiglitazone; Reyataz; Riboflavin; Ritonavir; Ritonavir (Norvir); Rosiglitazone; Rosiglitazone maleate; ST200; SUSTIVA; Saquinavir; Serostim®[somatropin (rDNA origin) for injection]; Setmelanotide; Simvastatin; Somatropin; Standard continuous antiretroviral therapy; Stavudine; Sulfate; TAT4 Gel concentration A; TAT4 Gel concentration B; TH9507; TRUVADA; Tenofovir; Tenofovir DF; Tenofovir Disoproxil Fumarate; Tenofovir disoproxil; Tesamorelin; Tesamorelin (Egrifta); Testosterone; Thiamine; Tipranavir; Total Dietary Replacement; Use of lipid-lowering drugs.; VOLANESORSEN SODIUM, ApoC-III Antisense Oligonucleotide; Viral load driven treatment interruption; Volanesorsen; Zidovudine; [N-trans-3-Hexenoyl] Human Growth Hormone Releasing Factor (1-44) Acetate

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00006412 (ClinicalTrials.gov)	July 2002	13/10/2000	Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood Lipids	A Prospective, Multicenter, Randomized Trial Comparing the Efficacy and Safety of Fenofibrate Versus Pravastatin in HIV-Infected Subjects With Lipid Abnormalities	HIV Infections;Lipodystrophy	Drug: Pravastatin sodium;Drug: Fenofibrate	National Institute of Allergy and Infectious Diseases (NIAID)	NULL	Completed	18 Years	N/A	Both	630	Phase 3	United States;Puerto Rico
2	NCT00227500 (ClinicalTrials.gov)	July 2001	27/9/2005	Pravastatin for Hyperlipidaemia in HIV.	A Randomised, Double-Blind Study of Pravastatin for the Treatment of Hyperlipidaemia in Patients With HIV	HIV Infections;Lipid Metabolism;Glucose Metabolism;Metabolic Abnormality;Lipodystrophy;Cardiovascular Disease	Drug: Pravastatin	Kirby Institute	The University of New South Wales;National Heart, Lung, and Blood Institute (NHLBI);Garvan Institute of Medical Research;St Vincent's Hospital, Sydney	Completed	18 Years	N/A	Both	40	Phase 4	Australia
3	NCT00017758 (ClinicalTrials.gov)	June 2001	11/6/2001	The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs	The Effect of Efavirenz and Nelfinavir on the Pharmacokinetics of Hydroxymethylglutaryl Coenzyme A Reductase Inhibitors	HIV Infections;HIV Seronegativity;Lipodystrophy	Drug: Pravastatin sodium;Drug: Simvastatin;Drug: Atorvastatin calcium;Drug: Nelfinavir mesylate;Drug: Efavirenz	National Institute of Allergy and Infectious Diseases (NIAID)	NULL	Completed	18 Years	60 Years	Both	56	Phase 1	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00006412
(ClinicalTrials.gov)

July 2002

13/10/2000

Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood Lipids

A Prospective, Multicenter, Randomized Trial Comparing the Efficacy and Safety of Fenofibrate Versus Pravastatin in HIV-Infected Subjects With Lipid Abnormalities

HIV Infections;Lipodystrophy

Drug: Pravastatin sodium;Drug: Fenofibrate

National Institute of Allergy and Infectious Diseases (NIAID)

NULL

Completed

18 Years

N/A

Both

630

Phase 3

United States;Puerto Rico

NCT00227500
(ClinicalTrials.gov)

July 2001

27/9/2005

Pravastatin for Hyperlipidaemia in HIV.

A Randomised, Double-Blind Study of Pravastatin for the Treatment of Hyperlipidaemia in Patients With HIV

HIV Infections;Lipid Metabolism;Glucose Metabolism;Metabolic Abnormality;Lipodystrophy;Cardiovascular Disease

Drug: Pravastatin

Kirby Institute

The University of New South Wales;National Heart, Lung, and Blood Institute (NHLBI);Garvan Institute of Medical Research;St Vincent's Hospital, Sydney

Completed

18 Years

N/A

Both

Phase 4

Australia

NCT00017758
(ClinicalTrials.gov)

June 2001

11/6/2001

The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs

The Effect of Efavirenz and Nelfinavir on the Pharmacokinetics of Hydroxymethylglutaryl Coenzyme A Reductase Inhibitors

HIV Infections;HIV Seronegativity;Lipodystrophy

Drug: Pravastatin sodium;Drug: Simvastatin;Drug: Atorvastatin calcium;Drug: Nelfinavir mesylate;Drug: Efavirenz

National Institute of Allergy and Infectious Diseases (NIAID)

NULL

Completed

18 Years

60 Years

Both

Phase 1

United States